Introduction Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists have rapidly become integral in the management of type 2 diabetes, obesity, and metabolic diseases due to their effects on glycemic control and weight loss. A key mechanism underlying their efficacy is delayed gastric emptying, which raises concerns in procedural settings such as upper endoscopy, where retained gastric contents may increase the risk of aspiration.
Introduction
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists have rapidly become integral in the management of type 2 diabetes, obesity, and metabolic diseases due to their effects on glycemic control and weight loss. A key mechanism underlying their efficacy is delayed gastric emptying, which raises concerns in procedural settings such as upper endoscopy, where retained gastric contents may increase the risk of aspiration. Despite widespread adoption of precautionary guidelines recommending withholding these agents before procedures, robust prospective evidence has been lacking.
Problem Statement
Current clinical practice is largely guided by expert opinion and limited retrospective data, leading to variability in recommendations regarding whether GLP-1/GIP agonists should be withheld before endoscopy. This uncertainty has practical implications, including procedure delays, cancellations, and potential compromise of metabolic control, highlighting the need for high-quality randomized evidence.
Summary
The OCULUS randomised clinical trial demonstrated that continuing GLP-1/GIP agonists significantly increased clinically relevant residual gastric volume compared to holding one dose before endoscopy (25% vs 3.1%). However, importantly, this did not translate into an increased rate of aspiration-related adverse events. Notably, patients undergoing combined procedures with a prior clear liquid diet showed negligible risk, suggesting a potential mitigating strategy.
Overall, the study provides the first high-quality evidence supporting a balanced, individualised approach, where holding medication reduces gastric residue, but continuation may still be safe in selected settings, particularly with appropriate dietary preparation.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.